TP53 and endometrial cancer: In molecular analysis, pathogenic CTNNB1 mutations involving exon 3 were identified in all 14 patients with CHEC [4, 5], and the majority of the 14 cases were considered as copy number low, except for two P53 mutation cases, according to the Cancer Genome Atlas (TCGA) molecular classification of endometrial cancer.